Toomey, S., Eustace, A. J., Fay, J., Sheehan, K. M., Carr, A., Milewska, M., . . . Hennessy, B. T. (2017). Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. Breast Cancer Res.
Dyfyniad Arddull ChicagoToomey, Sinead, et al. "Impact of Somatic PI3K Pathway and ERBB Family Mutations On Pathological Complete Response (pCR) in HER2-positive Breast Cancer Patients Who Received Neoadjuvant HER2-targeted Therapies." Breast Cancer Res 2017.
Dyfyniad MLAToomey, Sinead, et al. "Impact of Somatic PI3K Pathway and ERBB Family Mutations On Pathological Complete Response (pCR) in HER2-positive Breast Cancer Patients Who Received Neoadjuvant HER2-targeted Therapies." Breast Cancer Res 2017.